No Data
No Data
Do Xiamen Amoytop Biotech's (SHSE:688278) Earnings Warrant Your Attention?
Sinolink Securities: The large pharmaceutical sector is a key point in the mid-year report, and it is expected to see a overall recovery in the pharmaceutical sector in the second half of the year.
Looking ahead to the second half of the year, with the decline in the base, the recovery of procurement sentiment, and the stabilization of policy expectations, I am bullish on the recovery of demand for pharmaceutical and medical device products within hospitals, as well as the acceleration of performance growth. The pharmaceutical sector is expected to experience an overall reversal in the second half of the year.
Xiamen Amoytop Biotech Fiscal 2024 Profit Jumps 51%, Operating Income Up 32%; Shares Surge 14%
Xiamen Amoytop Biotech: Half-year report for the year 2024.
Xiamen Amoytop Biotech: Summary of Half-Year Report in 2024.
Xiamen Amoytop Biotech (688278.SH): Proposes to launch a restricted stock incentive plan for 6 million shares.
GeLonghui, August 21st | Xiamen Amoytop Biotech (688278.SH) announced its 2024 restricted stock incentive plan. The plan proposes to grant 6 million restricted stocks to the incentive target, accounting for 1.47% of the total 406.8 million shares of the company's stock when the plan was announced. The plan will initially grant 677 individuals the restricted stocks, with the initial grant price at 39.80 yuan per share, and the reserved portion of the grant price will be the same as the initial grant.
No Data
No Data